Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling


B-cell antigen receptor (BCR) expression is an important feature of chronic lymphocytic leukaemia (CLL), one of the most prevalent B-cell neoplasias in Western countries1. The presence of stereotyped and quasi-identical BCRs in different CLL patients suggests that recognition of specific antigens might drive CLL pathogenesis. Here we show that, in contrast to other B-cell neoplasias, CLL-derived BCRs induce antigen-independent cell-autonomous signalling, which is dependent on the heavy-chain complementarity-determining region (HCDR3) and an internal epitope of the BCR. Indeed, transferring the HCDR3 of a CLL-derived BCR provides autonomous signalling capacity to a non-autonomously active BCR, whereas mutations in the internal epitope abolish this capacity. Because BCR expression was required for the binding of secreted CLL-derived BCRs to target cells, and mutations in the internal epitope reduced this binding, our results indicate a new model for CLL pathogenesis, with cell-autonomous antigen-independent signalling as a crucial pathogenic mechanism.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: CLL-derived BCRs possess autonomous signalling capacity.
Figure 2: CLL BCRs induce cell-autonomous signalling.
Figure 3: Autonomous signalling of CLL-derived BCRs is mediated by the recognition of a BCR-intrinsic epitope.
Figure 4: Cell-autonomous Ca 2+ signalling is elevated in primary CLL B cells.


  1. Morton, L. M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107, 265–276 (2006)

    CAS  Article  Google Scholar 

  2. Ghiotto, F. et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J. Clin. Invest. 113, 1008–1016 (2004)

    CAS  Article  Google Scholar 

  3. Stamatopoulos, K. et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 109, 259–270 (2007)

    CAS  Article  Google Scholar 

  4. Bikos, V. et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 26, 1638–1646 (2012)

    CAS  Article  Google Scholar 

  5. Widhopf, G. F., II et al. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 104, 2499–2504 (2004)

    Article  Google Scholar 

  6. Ghia, P., Chiorazzi, N. & Stamatopoulos, K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J. Intern. Med. 264, 549–562 (2008)

    CAS  Article  Google Scholar 

  7. Stevenson, F. K., Krysov, S., Davies, A. J., Steele, A. J. & Packham, G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118, 4313–4320 (2011)

    CAS  Article  Google Scholar 

  8. Köhler, F. et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 29, 912–921 (2008)

    Article  Google Scholar 

  9. Übelhart, R. et al. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nature Immunol. 11, 759–765 (2010)

    Article  Google Scholar 

  10. Hervé, M. et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. 115, 1636–1643 (2005)

    Article  Google Scholar 

  11. Sthoeger, Z. M. et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med. 169, 255–268 (1989)

    CAS  Article  Google Scholar 

  12. Meixlsperger, S. et al. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 26, 323–333 (2007)

    CAS  Article  Google Scholar 

  13. Bichi, R. et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99, 6955–6960 (2002)

    ADS  CAS  Article  Google Scholar 

  14. Herling, M. et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 114, 4675–4686 (2009)

    CAS  Article  Google Scholar 

  15. Yan, X. J. et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 103, 11713–11718 (2006)

    ADS  CAS  Article  Google Scholar 

  16. Binder, M. et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 117, 1891–1900 (2011)

    CAS  Article  Google Scholar 

  17. Kulathu, Y., Grothe, G. & Reth, M. Autoinhibition and adapter function of Syk. Immunol. Rev. 232, 286–299 (2009)

    CAS  Article  Google Scholar 

  18. Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563–574 (2011)

    CAS  Article  Google Scholar 

  19. Seiler, T. et al. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood 114, 3615–3624 (2009)

    CAS  Article  Google Scholar 

  20. Buchner, M. et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115, 4497–4506 (2010)

    CAS  Article  Google Scholar 

  21. Suljagic, M. et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ–TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 116, 4894–4905 (2010)

    CAS  Article  Google Scholar 

  22. Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010)

    CAS  Article  Google Scholar 

  23. Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors . Science 301, 1374–1377 (2003)

    ADS  CAS  Article  Google Scholar 

  24. Tiller, T. et al. Development of self-reactive germinal center B cells and plasma cells in autoimmune FcγRIIB-deficient mice . J. Exp. Med. 207, 2767–2778 (2010)

    CAS  Article  Google Scholar 

  25. Bertinetti, C. et al. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli . Eur. J. Haematol. 77, 395–402 (2006)

    CAS  Article  Google Scholar 

  26. Osterroth, F. et al. Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination. J. Immunol. Methods 229, 141–153 (1999)

    CAS  Article  Google Scholar 

  27. Su, Y. W. & Jumaa, H. LAT links the Pre-BCR to calcium signaling. Immunity 19, 295–305 (2003)

    CAS  Article  Google Scholar 

  28. Storch, B., Meixlsperger, S. & Jumaa, H. The Ig-α ITAM is required for efficient differentiation but not proliferation of pre-B cells. Eur. J. Immunol. 37, 252–260 (2007)

    CAS  Article  Google Scholar 

Download references


We thank C. Croce for providing the TCL1 mice, M. Reth and P. Nielsen for scientific discussion and reading the manuscript, C. Wehr for help cloning TCL1-derived BCRs, A. Ott, A. Würch, S. Hopitz and B. Wehrle for help with FACS experiments and cloning, and D. Pfeifer and M. Pantic for providing clinical data. This work was supported by the Deutsche Krebshilfe (Project 108935), the Deutsche Forschungsgemeinschaft (SFB746 and JU 463/2-1) and the Excellence Initiative of the German Federal and State Governments (GSC-4, Spemann Graduate School).

Author information

Authors and Affiliations



M.D.-v.M., R.Ü., D.S., F.K. and M.P.B. conducted cloning of BCRs. M.D.-v.M., R.Ü. and D.S. performed measurements of BCR surface expression and calcium flux and performed soluble BCR-binding assays. M.D.-v.M. and T.W. performed quantitative reverse-transcriptase PCR experiments. M.B. performed the NF-κB activity ELISA. E.S. analysed Vh region sequences from patient samples. M.D.-v.M. and M.F. performed single-cell Ca2+ measurements. D.H. and H.W. tested the polyreactivity of CLL and TCL1 receptors. K.Z. and H.V. conducted the characterization of lymphoma patients and provided samples. M.D.-v.M., T.W., F.K. and H.J. wrote the manuscript. H.J. designed experiments. All authors discussed the results and commented on the manuscript.

Corresponding author

Correspondence to Hassan Jumaa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-6 and Supplementary Table 1. (PDF 9026 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Minden, Mv., Übelhart, R., Schneider, D. et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489, 309–312 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing